Partner Headlines - THRX

  1. Seth Klarman Keeps Buying LNG, KERX, PBF And Keeps Selling THRX

    GuruFocus
  2. Bank Of America Q3 Small & Mid-Cap Biotech Preview

    Benzinga
  3. Data Published on Anoro(R) Ellipta(R) Demonstrate Improved Lung ...

    GuruFocus
  4. Drug M&A Boom Driven By Long-Term Trends: PwC

    IBD
  5. Barron's Recap: Ready To Wear?

    Benzinga
  6. UPDATE: Bank Of America Downgrades Theravance As Pricing Headwinds ...

    Benzinga
  7. UPDATE: Morgan Stanley Reiterates On Theravance As Slow Trends ...

    Benzinga
  8. Theravance, Inc. Appoints Theodore J. Witek, Jr. As Senior VP, ...

    Benzinga
  9. UPDATE: Stifel Downgrades Theravance Following Post-Split Accretion

    Benzinga
  10. Benzinga's Top Downgrades

    Benzinga
  11. UPDATE: Glaxo, Theravance Report Positive Data from Two Studies ...

    Benzinga
  12. Theravance Announces Positive Results From a Phase 2 Study of ...

    Benzinga
  13. Theravance Announces Initiation of Phase 2b Study With TD-42 ...

    Benzinga
  14. Glaxo's COPD Drug Gets European Green Light

    FoxBusiness
  15. Morgan Stanley Expects Theravance to Continue to Underperform ...

    Benzinga
  16. Top 2013 Drug Approvals: Pharma Stocks

    YCharts
  17. Positive data for asthma drug

    IBD
  18. Theravance, Glaxo COPD Drug Does Well In Asthma

    IBD
  19. Seth Klarman Buys Micron Technology, Theravance, PBF Energy, ...

    GuruFocus
  20. GlaxoSmithKline

    IBD
  21. US Stock Futures Signal Flat Start On Wall Street

    Benzinga
  22. Relvar Ellipta Approved in Japan for Treatment of Asthma

    Benzinga
  23. Glaxo, Theravance Confirm Positive CHMP Opinion for Relvar Ellipta

    Benzinga
  24. Glaxo, Theravance Confirms FDA Panel Has Recommended Approval ...

    Benzinga
  25. Theravance Reports Results from Phase 2B Study 0091 with TD-42 ...

    Benzinga
  26. Missed Klarman’s 47% Gainer? His Other Value Pick

    YCharts
  27. Seth Klarman's Top 5 Second Quarter Holdings

    GuruFocus
  28. Perrigo-Elan Merger Creates Unlikely Pharma Union

    IBD
  29. UPDATE: Stifel Nicolaus Cuts PT to $37 on Theravance Ahead of ...

    Benzinga
  30. Theravance to Offer $250 Million Convertible Subordinated Notes ...

    Benzinga
  31. Weekly Guru Bargains Highlights: PANL, THRX, ZNGA, LORL, AMRN

    GuruFocus
  32. Theravance Confirms Favorable Ruling from FDA Panel on VIBATIV

    Benzinga
  33. Theravance Offers FDA Briefing Documents for Panel Meeting on ...

    Benzinga
  34. Theravance Enters Agreement With Alfa Wassermann Worth Up To ...

    Benzinga
  35. The Baupost Group's Favorite Stocks

    Benzinga
  36. Theravance Inc. (THRX) Sr VP, CFO Michael W Aguiar sells 24,682 ...

    GuruFocus
  37. GSK and Theravance Announce Completion of the Phase III Programme ...

    Benzinga
  38. Weekly CFO Sells Highlight: SWN, BECN, NSIT, HOLX, QLTI, THRX

    GuruFocus
  39. Theravance Inc. (THRX) Sr VP, CFO Michael W Aguiar sells 60, ...

    GuruFocus
  40. Theravance Inc. (THRX) CEO Rick E Winningham sells 75,749 Shares

    GuruFocus
  41. A Peek Into The Market Before The Trading Starts

    Benzinga
  42. GSK and Theravance Announce Regulatory Submissions for FF/VI ...

    Benzinga
  43. Target, Amgen Among Stocks Hitting 52-Week Highs Wednesday

    FoxBusiness
  44. Dendreon, Pharmacyclics and Other Biotech Takeover Targets

    Benzinga
  45. Merck &, Questcor Pharmaceuticals, Other Stocks Hit 52-Week Highs ...

    FoxBusiness
  46. Health Care Sector Wrap

    FoxBusiness
  47. Health Care Sector Wrap

    FoxBusiness
  48. GSK and Theravance Announce Positive Results From Four Pivotal ...

    Benzinga
  49. Theravance Inc. Reports Operating Results (10-K)

    GuruFocus
  50. UPDATE: Morgan Stanley Initiates Underweight, $12 PT on Theravance

    Benzinga
  51. Morgan Stanley Initiates Theravance at Underweight

    Benzinga
  52. Afternoon Movers; Markets Moved Higher

    Benzinga
  53. Morning Market Losers

    Benzinga
  54. From Earlier: GSK and Theravance Announce Initial Outcomes From ...

    Benzinga
  55. UPDATE: Piper Jaffray Raises Price Target on Theravance to $35

    Benzinga
  56. Piper Jaffray Raises PT on Theravance to $35

    Benzinga
  57. Notable Put Options Activity in Theravance

    Benzinga
  58. Theravance Inc. (THRX) Sr VP, CFO Michael W Aguiar sells 10, ...

    GuruFocus
Trading Center